Boehringer Ingelheim and GENEART Collaborate to Provide DNA Therapeutics and Vaccines
News Jun 24, 2008
Boehringer Ingelheim and GENEART announce their technology and sales collaboration. The collaboration includes a transfer of Boehringer Ingelheim technology to GENEART for the production and purification of plasmid DNA. The two partner companies also plan to closely collaborate in the distribution and marketing of their complementary services.
The collaboration offers system solution for the development of DNA-based pharmaceuticals. GENEART will use the Boehringer Ingelheim production and purification technology to deliver DNA-based agents for research, development and preclinical studies. Boehringer Ingelheim will produce the pharmaceuticals under cGMP (current Good Manufacturing Practice) conditions for the subsequent clinical phases and the market.
Customers in research and industry additionally benefit from GENEART's expertise in software-assisted design of gene sequences and from the production of these improved (optimized) sequences via gene synthesis. Optimized genes are essential for the improvement of product properties, such as for the enhancement of immunogenicity and safety of DNA based pharmaceuticals.
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.
Researchers published today a detailed description of the complete genome of bread wheat, the world's most widely-cultivated crop. This work will pave the way for the production of wheat varieties better adapted to climate challenges, with higher yields, enhanced nutritional quality and improved sustainability.